By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Moleculin Biotech 

2575 West Bellfort
Suite 333
Houston  Texas  77054  U.S.A.
Phone: 713-300-5160 Fax: n/a


Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center, the world’s largest cancer research facility headquartered within the world’s largest medical center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.




Founder, Chairman, CEO, and Business Advisory Board Member: Walter V. Klemp

President and COO: Donald Picker

CMO: Robert Shepard, MD, FACP

Executive VP and CFO: Jonathan P. Foster

Business Advisory Board Member: Lori H. Bisson


Please click here for Moleculin Biotech's technology.

Key Statistics

Ownership: Public

Web Site: Moleculin Biotech
Symbol: MBRX


Company News
Moleculin Biotech (MBRX) Appoints Lead European Principal Investigator For Planned Annamycin Clinical Trial 7/6/2017 8:21:54 AM
Reminder: Moleculin Biotech (MBRX) Announces Conference Call To Discuss Recent New Discovery For Pancreatic Cancer And Business Update 6/29/2017 8:14:33 AM
Moleculin Biotech (MBRX) Announces Scientific Support For Research Endeavor At Mayo Clinic 6/26/2017 6:03:31 AM
Moleculin Biotech (MBRX) Announces Significant Discovery With Potential To Treat Pancreatic Cancer 6/21/2017 9:30:29 AM
Moleculin Biotech (MBRX) Announces Preparation To File An IND With The f-Star For WP1220 For Treatment Of Cutaneous T-Cell Lymphoma 6/13/2017 11:42:27 AM
Moleculin Biotech (MBRX) Issues Shareholder Update On FDA Designation Of Orphan Drug And IND Status For Annamycin 5/23/2017 2:11:42 PM
Moleculin Biotech (MBRX) Reports Financial Results For The First Quarter Ended March 31, 2017 5/16/2017 2:22:45 PM
Moleculin Biotech (MBRX) Receives Orphan Drug Designation For Annamycin For The Treatment Of Acute Myeloid Leukemia 3/22/2017 10:08:38 AM
Moleculin Biotech (MBRX) Announces Pricing Of $5 Million Underwritten Public Offering 2/10/2017 8:10:26 AM
Moleculin Biotech (MBRX) Presents Preclinical Data Of Novel Inhibitor Of Glycolysis At 28th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 12/13/2016 10:03:49 AM